JUPITER, FL -- A scientist at The Scripps Research Institute has been awarded $3.4 million from the National Institutes of Health to study the mode of action and the therapeutic potential of a new compound that blocks a step of HIV replication not targeted by current therapies.
Susana Valente, an assistant professor at Scripps Florida, is the principal investigator of the five-year grant. Valente will lead research into the viral protein known as Tat, a potent activator of HIV gene expression, and a Tat inhibitor that is extremely effective at reducing viral output from acutely and chronically infected cells in culture. Most antiretroviral compounds only block new infections; a Tat inhibitor can reduce viral replication from cells already infected.
"Our main goal with this grant is to fully understand the underlying mechanism of this new compound's inhibitory strength against Tat," Valente said, "and then to evaluate its therapeutic potential in animal models. If that's successful, the next obvious step would be to optimize it for use in human clinical trials."
Despite recent advances, HIV/AIDS continues its deadly global march, affecting more than 35 million individuals worldwide. The virus stubbornly persists in infected subjects despite Highly Active Antiretroviral Therapy (HAART). This residual viremia is the major hurdle for HIV eradication. Valente's newly identified Tat inhibitor defines a novel class of anti-viral drugs that could potentially inhibit viral production from stable reservoirs and reduce viral persistency during HAART.
"Initially, we though this compound was targeting another protein, but the data suggested that it was actually an inhibitor of Tat," Valente said. "We soon discovered we had a powerful inhibitor of HIV-1 transcription in our handsand that's where we are today. This work was made possible by the great ongoing collaboration with Professor Phil Baran of Scripps California."
'/>"/>
| Contact: Mika Ono mikaono@scripps.edu 858-784-2052 Scripps Research Institute Source:Eurekalert |
Related biology news :
1. Scripps Research scientists uncover new role for gene in maintaining steady weight
2. Scripps Research team finds a weak spot on deadly ebolavirus
3. Scripps research scientists develop brand new class of small molecules through innovative chemistry
4. Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
5. Scripps research team achieves critical step to opening elusive class of compounds to drug discovery
6. Scripps Research scientist awarded $500,000 grant to study Parkinsons disease
7. Scripps launches whole genome sequencing study to find root causes of idiopathic diseases
8. Scripps and Complete Genomics to collaborate on genetic research study on healthy aging
9. 2 Scripps Research scientists win prestigious NIH Innovator Awards
10. Scripps Research team overcomes major obstacle for stem cell therapies and research
11. Scripps Research scientists pinpoint shape-shifting mechanism critical to protein signaling
 |
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |